Accéder au contenu
Merck

The roles of interferon regulatory factors 1 and 2 in the progression of human pancreatic cancer.

Pancreas (2014-03-19)
Toshitaka Sakai, Hirosato Mashima, Yumi Yamada, Takashi Goto, Wataru Sato, Takahiro Dohmen, Kentaro Kamada, Masato Yoshioka, Hiroshi Uchinami, Yuzo Yamamoto, Hirohide Ohnishi
RÉSUMÉ

Pancreatic cancer is one of the most malignant diseases worldwide. Interferon regulatory factor (IRF) 1 and IRF2 function as a tumor suppressor and oncoprotein, respectively, in several types of cancers. We investigated whether IRF1 and IRF2 are involved in the progression of pancreatic cancer. We examined the expressions of IRF1 and IRF2 in pancreatic cancer specimens and analyzed the association with clinicopathologic features. We evaluated the biological effects of IRF1 and IRF2 using a pancreatic cancer cell line. The expression levels of IRF1 and IRF2 were decreased and increased, respectively, in the pancreatic cancer cells compared with those observed in the paired normal areas. A higher expression of IRF1 was associated with better features of tumor differentiation, infiltration depth, tumor size, and survival, whereas that of IRF2 was associated with a worse feature of tumor infiltration depth. Interferon regulatory factor 2-overexpressing PANC-1 cells exhibited an increase in cell growth, less apoptotic features, and chemoresistance to gemcitabine treatment. In contrast, IRF1-overexpressing cells exhibited the opposite characteristics. Interferon regulatory factors 1 and 2 may regulate the progression of pancreatic cancer by functioning as an antioncoprotein and oncoprotein, respectively. These molecules may serve as potential targets of therapy.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Fluorescein, for fluorescence, free acid
Fluorescein, European Pharmacopoeia (EP) Reference Standard